KYODO NEWS IMAGELINK

報道写真の購入なら共同通信イメージズ

  • 免疫原性
  • レベル
  • 世界初
  • 中国工程院
  • 令和
  • 免疫反応
  • 楊志剛
  • 王迪
  • 確認
  • 筋肉注射

「免疫原」の写真・映像

絞り込み
  • 提供元
  • 日付
  • 種類
  • 向き
  • カテゴリ
並び順
  • 古い順
17
( 1 17 件を表示)
  • 1
17
( 1 17 件を表示)
絞り込み
並び順
  • 古い順
  • 2016年08月02日
    Zika Virus Investigational DNA Vaccine

    A healthy volunteer receives the NIAID Zika virus investigational DNA vaccine as part of an early-stage trial to test the vaccine‘s safety and immunogenicity. This is the first administration of this vaccine in a human. Credit: NIAID. .、クレジット:IMAGE POINT FR / NIH / NIAID/Universal Images Group/共同通信イメージズ

    商品コード: 2021030103437

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082704529

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082704725

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082704667

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082704573

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082704582

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082700912

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082704652

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082704790

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082704788

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082700939

  • 2020年08月25日
    Pfizer Claims 90 Percent Efficiency with COVID-19 Vaccine

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020111007796

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082704999

  • 2020年08月26日
    Company logos displayed on smartphone in Brazil - 26 Aug 2020

    July 4, 2020, Brazil: In this photo illustration the ImmunoGen logo seen displayed on a smartphone. (Credit Image: © Rafael Henrique/SOPA Images via ZUMA Wire)、クレジット:©Rafael Henrique/SOPA Images via ZUMA Wire/共同通信イメージズ

    商品コード: 2020082801688

  • 01:12.86
    2021年07月31日
    「新華社」中国製吸入型ワクチンの第1相臨床試験結果、英医学誌に発表

    中国工程院の陳薇(ちん・び)院士(アカデミー会員)率いる科学研究チームが開発した噴霧吸入型の新型コロナウイルスワクチンの第1相臨床試験データがこのほど、英医学誌「ランセット感染症」の電子版に掲載された。新型コロナワクチンの粘膜免疫に関する臨床試験の結果が公開されるのは世界初となる。臨床試験が行われたのはアデノウイルスベクターワクチンで、第1相試験の結果、高い安全性と免疫原性が確認された。1回分の分量は筋肉注射の5分の1程度で済み、免疫反応のレベルは筋肉注射1回分に相当するという。(記者/王逸濤、楊志剛、張振威、王迪、王静怡) =配信日: 2021(令和3)年7月31日、クレジット:新華社/共同通信イメージズ

    商品コード: 2021073110467

  • 2022年01月13日
    AstraZeneca COVID-19 Vaccine Booster

    January 13, 2022, Asuncion, Paraguay: Illustration: A syringe is seen in front of AstraZeneca logo, visual representation of virus and vials labeled ‘‘COVID-19 Vaccine‘‘. AstraZeneca has posted preliminary data from an ongoing safety and immunogenicity trial of its COVID-19 shot, Vaxzevria. The new data showed increased antibody response against Beta, Delta, Alpha and Gamma SARS-CoV-2 variants, following third dose booster. Additional analysis showed increased antibody response to Omicron after a third dose. (Credit Image: © Andre M. Chang/ZUMA Press Wire)、クレジット:©Andre M. Chang/ZUMA Press Wire/共同通信イメージズ

    商品コード: 2022011408894

  • 2022年01月13日
    AstraZeneca COVID-19 Vaccine Booster

    January 13, 2022, Asuncion, Paraguay: Illustration: A syringe is seen in front of AstraZeneca logo, visual representation of virus and vials labeled ‘‘COVID-19 Vaccine‘‘. AstraZeneca has posted preliminary data from an ongoing safety and immunogenicity trial of its COVID-19 shot, Vaxzevria. The new data showed increased antibody response against Beta, Delta, Alpha and Gamma SARS-CoV-2 variants, following third dose booster. Additional analysis showed increased antibody response to Omicron after a third dose. (Credit Image: © Andre M. Chang/ZUMA Press Wire)、クレジット:©Andre M. Chang/ZUMA Press Wire/共同通信イメージズ

    商品コード: 2022011406141

  • 1